(Q30453014)

English

The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Shannon N. Westin

2

object named as

Shannon N Westin

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Leigh A Cantrell

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Linda Van Le

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

8 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1220-1226

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Erythropoietin for patients with malignant disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Erythropoietin or Darbepoetin for patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Tumor progression associated with erythropoiesis-stimulating agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Absence of functional EpoR expression in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

21 January 2018

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25590

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25590

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30453014&oldid=1855912117"